MapLight Therapeutics, Inc. Common Stock - Asset Resilience Ratio
MapLight Therapeutics, Inc. Common Stock (MPLT) has an Asset Resilience Ratio of 63.28% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MapLight Therapeutics, Inc. Common Stock (MPLT) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how MapLight Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see MapLight Therapeutics, Inc. Common Stock total assets.
Liquid Assets Composition Over Time
This chart breaks down MapLight Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of MapLight Therapeutics, Inc. Common Stock's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $233.09 Million | 63.28% |
| Total Liquid Assets | $233.09 Million | 63.28% |
Asset Resilience Insights
- Very High Liquidity: MapLight Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 63.28% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MapLight Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare MapLight Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for MapLight Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual Asset Resilience Ratio data for MapLight Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 53.88% | $258.37 Million | $479.51 Million | +2.36pp |
| 2024-12-31 | 51.52% | $70.54 Million | $136.92 Million | -- |
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irrit… Read more